Rewarding innovation with expedited drug approval
The value of priority review vouchers will ultimately be dictated by market forces. Easy accessibility to information is crucial to help create an environment where players can derive the greatest possible value from voucher transactions.
BIO Ventures for Global Health aims to facilitate the transaction of priority review vouchers by centralizing information for all interested parties.
Voucher Tracking
Track the current status of vouchers that have been awarded.
Current Vouchers
The first Priority Review Voucher issued under the Food and Drug Administration Amendments Act of 2007 (FDAAA) was announced on April 8, 2009 by the US Food and Drug Administration (FDA) and was awarded to Novartis Pharmaceuticals Corp. in conjunction with the FDA’s approval for use in the United States of the antimalarial drug Coartem (artemether–lumefantrine) manufactured by Novartis.
PRV Tracking Number: PRV 22268
Date voucher earned: April 7, 2009
Entity earning voucher: Novartis Pharmaceuticals Corp.
Product qualifying for the voucher: Coartem® (artemether 20 mg/lumefantrine 120 mg)
Clinical application of the product: Artemisinin-based combination therapy (ACT) for Malaria
Date(s) voucher transferred: TBD
Entities involved in transfer(s): TBD
Details (if known) of transaction(s): TBD
Current status of voucher (viable or used): Viable
As vouchers are awarded and start being traded, this page will track the current status of each voucher issued.
Products to Watch
View the product development pipelines for several global health products on the BVGH R&D Library. BIO Ventures for Global Health tracks the development of products for a number of neglected diseases. Not all products or diseases that BVGH tracks are eligible to earn vouchers, and not all PRV-eligible diseases are included. BVGH works to regularly update this pipeline and to add new products and diseases as the information becomes available.
Tracking PRV Eligible Products
BIO Ventures for Global Health tracks the development of products for a number of neglected diseases. Not all products or diseases that BVGH tracks are eligible to earn vouchers, and not all PRV-eligible diseases are included.